Logo image of SCYX

SCYNEXIS INC (SCYX) Stock Fundamental Analysis

USA - NASDAQ:SCYX - US8112922005 - Common Stock

1.12 USD
+0.03 (+2.75%)
Last: 9/19/2025, 8:00:02 PM
1.12 USD
0 (0%)
After Hours: 9/19/2025, 8:00:02 PM
Fundamental Rating

4

Overall SCYX gets a fundamental rating of 4 out of 10. We evaluated SCYX against 196 industry peers in the Pharmaceuticals industry. While SCYX seems to be doing ok healthwise, there are quite some concerns on its profitability. SCYX has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

SCYX had negative earnings in the past year.
In the past year SCYX has reported a negative cash flow from operations.
In the past 5 years SCYX reported 4 times negative net income.
In the past 5 years SCYX reported 4 times negative operating cash flow.
SCYX Yearly Net Income VS EBIT VS OCF VS FCFSCYX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

Looking at the Return On Assets, with a value of -32.16%, SCYX is in line with its industry, outperforming 48.47% of the companies in the same industry.
With a Return On Equity value of -43.89%, SCYX perfoms like the industry average, outperforming 55.61% of the companies in the same industry.
Industry RankSector Rank
ROA -32.16%
ROE -43.89%
ROIC N/A
ROA(3y)-14.27%
ROA(5y)-24.82%
ROE(3y)-636.53%
ROE(5y)-446.25%
ROIC(3y)N/A
ROIC(5y)N/A
SCYX Yearly ROA, ROE, ROICSCYX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

Looking at the Gross Margin, with a value of 114.98%, SCYX belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
In the last couple of years the Gross Margin of SCYX has remained more or less at the same level.
SCYX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 114.98%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.8%
GM growth 5YN/A
SCYX Yearly Profit, Operating, Gross MarginsSCYX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K

More info and screens

6

2. Health

2.1 Basic Checks

SCYX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SCYX has more shares outstanding
SCYX has more shares outstanding than it did 5 years ago.
SCYX has a worse debt/assets ratio than last year.
SCYX Yearly Shares OutstandingSCYX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
SCYX Yearly Total Debt VS Total AssetsSCYX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

SCYX has an Altman-Z score of -8.31. This is a bad value and indicates that SCYX is not financially healthy and even has some risk of bankruptcy.
SCYX has a Altman-Z score of -8.31. This is in the lower half of the industry: SCYX underperforms 65.82% of its industry peers.
SCYX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.31
ROIC/WACCN/A
WACC9.85%
SCYX Yearly LT Debt VS Equity VS FCFSCYX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

SCYX has a Current Ratio of 5.20. This indicates that SCYX is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 5.20, SCYX is doing good in the industry, outperforming 70.92% of the companies in the same industry.
SCYX has a Quick Ratio of 5.20. This indicates that SCYX is financially healthy and has no problem in meeting its short term obligations.
SCYX has a Quick ratio of 5.20. This is in the better half of the industry: SCYX outperforms 70.92% of its industry peers.
Industry RankSector Rank
Current Ratio 5.2
Quick Ratio 5.2
SCYX Yearly Current Assets VS Current LiabilitesSCYX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

6

3. Growth

3.1 Past

SCYX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.44%, which is quite impressive.
Looking at the last year, SCYX shows a very negative growth in Revenue. The Revenue has decreased by -66.43% in the last year.
The Revenue has been growing by 99.01% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)44.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.33%
Revenue 1Y (TTM)-66.43%
Revenue growth 3Y-34.22%
Revenue growth 5Y99.01%
Sales Q2Q%85.33%

3.2 Future

SCYX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.70% yearly.
The Revenue is expected to grow by 36.50% on average over the next years. This is a very strong growth
EPS Next Y38.57%
EPS Next 2Y82.67%
EPS Next 3Y68.75%
EPS Next 5Y23.7%
Revenue Next Year48.11%
Revenue Next 2Y124.59%
Revenue Next 3Y108.87%
Revenue Next 5Y36.5%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
SCYX Yearly Revenue VS EstimatesSCYX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M
SCYX Yearly EPS VS EstimatesSCYX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -10 -20 -30 -40 -50

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

SCYX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 1.90, the valuation of SCYX can be described as very cheap.
SCYX's Price/Forward Earnings ratio is rather cheap when compared to the industry. SCYX is cheaper than 99.49% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.86. SCYX is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 1.9
SCYX Price Earnings VS Forward Price EarningsSCYX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SCYX Per share dataSCYX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
SCYX's earnings are expected to grow with 68.75% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y82.67%
EPS Next 3Y68.75%

More info and screens

0

5. Dividend

5.1 Amount

SCYX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SCYNEXIS INC

NASDAQ:SCYX (9/19/2025, 8:00:02 PM)

After market: 1.12 0 (0%)

1.12

+0.03 (+2.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-13 2025-08-13/amc
Earnings (Next)11-04 2025-11-04/amc
Inst Owners29.92%
Inst Owner Change-5.88%
Ins Owners2.24%
Ins Owner Change3.93%
Market Cap46.95M
Analysts84.44
Price Target4.76 (325%)
Short Float %1.21%
Short Ratio2.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.07%
Min EPS beat(2)27.76%
Max EPS beat(2)38.38%
EPS beat(4)4
Avg EPS beat(4)36.63%
Min EPS beat(4)20.51%
Max EPS beat(4)59.89%
EPS beat(8)6
Avg EPS beat(8)23.48%
EPS beat(12)8
Avg EPS beat(12)7.4%
EPS beat(16)11
Avg EPS beat(16)17.41%
Revenue beat(2)2
Avg Revenue beat(2)395.48%
Min Revenue beat(2)22.61%
Max Revenue beat(2)768.35%
Revenue beat(4)2
Avg Revenue beat(4)152.71%
Min Revenue beat(4)-90.6%
Max Revenue beat(4)768.35%
Revenue beat(8)5
Avg Revenue beat(8)170.56%
Revenue beat(12)8
Avg Revenue beat(12)116.76%
Revenue beat(16)9
Avg Revenue beat(16)82.59%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-15.38%
EPS NY rev (1m)0%
EPS NY rev (3m)15.87%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1191.45%
Revenue NY rev (1m)2.43%
Revenue NY rev (3m)-7.28%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 1.9
P/S 14.41
P/FCF N/A
P/OCF N/A
P/B 1.06
P/tB 1.06
EV/EBITDA N/A
EPS(TTM)-0.4
EYN/A
EPS(NY)0.59
Fwd EY52.52%
FCF(TTM)-0.57
FCFYN/A
OCF(TTM)-0.57
OCFYN/A
SpS0.08
BVpS1.06
TBVpS1.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -32.16%
ROE -43.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 114.98%
FCFM N/A
ROA(3y)-14.27%
ROA(5y)-24.82%
ROE(3y)-636.53%
ROE(5y)-446.25%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.8%
GM growth 5YN/A
F-Score4
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.2
Quick Ratio 5.2
Altman-Z -8.31
F-Score4
WACC9.85%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.33%
EPS Next Y38.57%
EPS Next 2Y82.67%
EPS Next 3Y68.75%
EPS Next 5Y23.7%
Revenue 1Y (TTM)-66.43%
Revenue growth 3Y-34.22%
Revenue growth 5Y99.01%
Sales Q2Q%85.33%
Revenue Next Year48.11%
Revenue Next 2Y124.59%
Revenue Next 3Y108.87%
Revenue Next 5Y36.5%
EBIT growth 1Y29.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-336.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-336.99%
OCF growth 3YN/A
OCF growth 5YN/A